Latest Breaking News On - Aptevo therapeutic - Page 1 : comparemela.com

Roth Capital Research Analysts Cut Earnings Estimates for Aptevo Therapeutics Inc (NASDAQ:APVO)

Roth Capital Research Analysts Cut Earnings Estimates for Aptevo Therapeutics Inc (NASDAQ:APVO)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesSecurities exchange commissionAptevo therapeutics incArmistice capitalAptevo therapeuticsFree reportRoth capitalAptevo therapeuticGet free reportTherapeutics incAptevo therapeutics daily

Q2 2024 EPS Estimates for Aptevo Therapeutics Inc Cut by Roth Capital (NASDAQ:APVO)

Q2 2024 EPS Estimates for Aptevo Therapeutics Inc Cut by Roth Capital (NASDAQ:APVO)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesArmistice capitalAptevo therapeutics incAptevo therapeuticsFree reportRoth capitalAptevo therapeuticGet free reportTherapeutics incAptevo therapeutics daily

Aptevo Therapeutics Inc (NASDAQ:APVO) Expected to Post Quarterly Sales of $3 43 Million

Analysts predict that Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Rating) will report sales of $3.43 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Aptevo Therapeutics’ earnings, with the lowest sales estimate coming in at $3.25 million and the highest estimate coming in at $3.60 million. Aptevo Therapeutics posted […]

United statesPiper sandlerSchonfeld strategic advisorsAptevo therapeutics incZacks investment researchVanguard group incYork mellon corpMoors cabot incAptevo therapeuticsGet ratingAptevo therapeuticInvestment researchNew york mellon corpStrategic advisorsCapital managementTherapeutics inc

$3 75 Million in Sales Expected for Aptevo Therapeutics Inc (NASDAQ:APVO) This Quarter

Analysts forecast that Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Rating) will report $3.75 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Aptevo Therapeutics’ earnings. The highest sales estimate is $4.00 million and the lowest is $3.50 million. Aptevo Therapeutics reported sales of $2.42 million during the same […]

United statesSchonfeld strategic advisorsAptevo therapeutics incGeode capital managementZacks investment researchBlackrock incMoors cabot incAptevo therapeuticsGet ratingAptevo therapeuticInvestment researchCapital managementStrategic advisorsTherapeutics incNasdaq apvo

Zacks: Analysts Anticipate Aptevo Therapeutics Inc (NASDAQ:APVO) to Announce -$1 24 Earnings Per Share

Brokerages expect that Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Rating) will report ($1.24) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Aptevo Therapeutics’ earnings. The lowest EPS estimate is ($1.54) and the highest is ($0.93). Aptevo Therapeutics reported earnings per share of ($1.74) in the same quarter […]

Thomson reuterSchonfeld strategic advisorsMorgan stanleyAptevo therapeutics incFranklin resources incMoors cabot incZacks investment researchAptevo therapeuticsGet ratingAptevo therapeuticInvestment researchStrategic advisorsCapital managementFranklin resourcesNasdaq apvo